Archive for July 20th, 2009
Historical Perspective — Emergence of Influenza A (H1N1) Viruses
N Engl J. of Medicine July 16, 2009 V.361 N3. p.279-285
Review Article
Current Concepts
Shanta M. Zimmer, M.D., and Donald S. Burke, M.D.
abstract
http://content.nejm.org/cgi/content/full/361/3/279?query=TOC
Add comment July 20, 2009
HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia
N Engl J. of Medicine July 16, 2009 V.361 N3. p.271-278
Clinical Therapeutics
Jessica A. Kahn, M.D., M.P.H.
abstract
http://content.nejm.org/cgi/content/short/361/3/271?query=TOC
Add comment July 20, 2009
The Persistent Legacy of the 1918 Influenza Virus
N Engl J. of Medicine July 16, 2009 V.361 N3. p.225-229
David M. Morens, M.D., Jeffery K. Taubenberger, M.D., Ph.D., and Anthony S. Fauci, M.D.
abstract
http://content.nejm.org/cgi/content/full/361/3/225?query=TOC
Add comment July 20, 2009
Bacterial Pneumonia and Pandemic Influenza Planning
EID August 2008, V.14 N.8
Ravindra K. Gupta,* Comments to Author Robert George,† and Jonathan S. Nguyen-Van-Tam‡
*John Radcliffe Hospital, Oxford, UK; †Health Protection Agency, London, UK; and ‡University of Nottingham, Nottingham, UK
Abstract
Pandemic influenza planning is well under way across the globe. Antiviral drugs and vaccines have dominated the therapeutic agenda. Far less work has been conducted on stockpiling and planning for deployment of antimicrobial drugs against secondary bacterial pneumonia, a cause of substantial illness and death in previous pandemics and epidemics. In the event of a pandemic, effective antimicrobial drug measures are expected to substantially benefit public health. We address issues regarding use of antimicrobial drugs as stocks of individual agents are diminished and the role of resistance surveillance in informing such policy. Furthermore, vaccination with polysaccharide and conjugate pneumococcal vaccines is considered as part of a pandemic strategy. Most illness and death from influenza are likely to occur in developing countries, where neuraminidase inhibitors and vaccines may be neither affordable nor available; thus, compared with industrialized countries, the benefits of treating bacterial complications in developing countries may be substantially greater.
Full Text
http://www.cdc.gov/EID/content/14/8/1187.htm
http://www.cdc.gov/EID/content/14/8/pdfs/1187.pdf
* * *
Add comment July 20, 2009
